Bortezomib, a first-generation proteasome inhibitor widely used in chemotherapy for
hematologic malignancy, has effective anti-cancer activity but often causes severe …

Improvements in screening, diagnosis and treatment of cancer has seen cancer mortality
substantially diminish in the past three decades. It is estimated there are almost 20 million …

Chemotherapy-induced peripheral neurotoxicity (CIPN) is a major dose-limiting side effect of
many anti-cancer agents, including taxanes, platinums, vinca alkaloids, proteasome …

Chemotherapeutic treatment with conventional drug formulations pose numerous
challenges, such as poor solubility, high cytotoxicity and serious off‐target side effects, low …

Simple Summary Chemotherapy-induced peripheral neuropathy (CIPN) is a common and
persistent complication of commonly used chemotherapy drugs. This article provides an …

Abstract Background and Aims The expanding use of chemotherapy in curative cancer
treatment has simultaneously resulted in a substantial and growing cohort of cancer …

Membrane transporters play a key role in determining the pharmacokinetic profile,
therapeutic safety, and efficacy of many chemotherapeutic drugs by regulating cellular influx …

Vincristine is a widely used chemotherapeutic drug for the treatment of multiple malignant
diseases that causes a dose-limiting peripheral neurotoxicity. There is no clinically effective …

Nucleoside reverse transcriptase inhibitors (NRTIs) are the backbone of highly active
antiretroviral therapy (HAART)—the current standard of care for treating human …

Bortezomib is the first-line standard and most effective chemotherapeutic for multiple
myeloma; however, bortezomib-induced peripheral neuropathy (BIPN) severely affects the …